ResearcherMedical University of South CarolinaActive in the last 2 years

Reeder M. Robinson

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5021918117. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.3390/biom15050645 ↗
A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17). Co-author DOI 10.3390/antib13040101 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Benjamin N. Christopher · 2 shared papers, 2024–2025 · strength 0.43
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645 ↗
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101 ↗
G. Aaron Hobbs · 2 shared papers, 2024–2025 · strength 0.43
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645 ↗
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101 ↗
John P O'Bryan · 2 shared papers, 2024–2025 · strength 0.43
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645 ↗
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101 ↗
Nathan G. Dolloff · 2 shared papers, 2024–2025 · strength 0.43
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645 ↗
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101 ↗
Denis C. Guttridge D · 1 shared paper, 2025 · strength 0.24
- Paper Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in … DOI 10.3390/biom15050645 ↗
Rachel A. Burge · 1 shared paper, 2024 · strength 0.20
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101 ↗
Julie B. Siegel · 1 shared paper, 2024 · strength 0.20
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101 ↗
Nancy Klauber‐DeMore · 1 shared paper, 2024 · strength 0.20
- Paper A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA… DOI 10.3390/antib13040101 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.